| 抗结核药物最新进展 |
| |
| 引用本文： | 卢曦,杨信怡,游雪甫.抗结核药物最新进展[J].齐鲁药事,2013,32(1):36-41. |
| |
| 作者姓名： | 卢曦 杨信怡 游雪甫 |
| |
| 作者单位： | 中国医学科学院/北京协和医学院,医药生物技术研究所,北京,100050 |
| |
| 基金项目： | 国家自然科学基金项目(81273427);中央级公益性科研院所基本科研业务费专项资金项目(IMBF201201);国家十二五科技重大专项(2012ZX09301002) |
| |
| 摘 要： | 结核病是病死率仅次于艾滋病的全球第二大感染性疾病。当前结核病的控制面临一系列挑战。世界卫生组织推荐的结核治疗方案疗程长,对敏感菌和耐药菌感染分别需6个月、20个月的持续治疗。现有抗结核一线化疗药仍为四十多年前所开发,品种有限,选择余地小。此外,多耐药结核病(MDR-TB)及广泛耐药结核病(XDR-TB)的流行,严重阻碍了结核病控制的进展。严峻的结核病防治形势急需抗结核新药的出现。近十年来,抗结核化疗新药研发在沉寂多年后取得了较明显进展。本文介绍了近年上市与处于临床及临床前研究阶段的抗结核新药。
|
| 关 键 词： | 结核分枝杆菌 抗结核新药 化学治疗 |
The latest progress in anti-tuberculosis agents |
| |
| LU Xi
,
YANG Xin-yi
,
YOU Xue-fu.The latest progress in anti-tuberculosis agents[J].qilu pharmaceutical affairs,2013,32(1):36-41. |
| |
| Authors: | LU Xi YANG Xin-yi YOU Xue-fu |
| |
| Institution: | (Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China) |
| |
| Abstract: | Tuberculosis(TB) is the second leading cause of death from an infectious disease worldwide,after HIV/AIDS.There are a series of challenges in control of TB.First,the treatment regimens recommended by World Health Organization require six or twenty months for the infections caused by susceptible and resistant TB strains,respectively.The current anti-TB drugs were developed over forty years which limit the therapeutic options against TB.Moreover,the prevalence of multidrug-resistant tuberculosis(MDR-TB) and extensively drug-resistant TB(XDR-TB) hinders the improvement in control of TB.The threat of TB highlights the need of novel anti-tuberculosis drugs.The past ten years had seen a significant progress in development of new anti-TB drugs after a long period of neglect.This article reviews the new anti-TB agents came on the market recently and those under preclinical and clinical development. |
| |
| Keywords: | Mycobacterium tuberculosis Anti-tuberculosis new drug Chemotherapy |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
